Focused on Partnerships
We are applying our drug developing expertise to design novel anti-cancer medicines that address serious unmet medical needs in oncology and autoimmune disease. Our team of experts is capable of creating mAbs, multi-specific antibodies and ADCs against targets of interest and providing phase I-ready assets to partners.
Our three unique assets targeting oxMIF, the key to drugging MIF:
- ON203: OncoOne’s optimized therapeutic mAb targeting oxMIF in solid tumors
- ON104: OncoOne’s oxMIF mAb specifically formulated for autoimmune disorders and severe inflammatory conditions
- ON102: a diagnostic radioimmunoconjugate targeting oxMIF for the detection of malignant solid tumors and metastases
- ON-05: the first asset from OncoOne’s proprietary PreTarg-it™ platform combining the tumor aggregation of oxMIF and radiotherapy in a powerful, yet highly targeted radioimmunoconjugate therapy
We value our cooperation with excellent public grantpartners
and are proud to partner with top-tier academic collaborators.
in Boston (USA) and Vienna (Austria)
from China, France, Germany, India, Italy, Netherlands, Northern Ireland, Switzerland, UK, US